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Summary
A collaborative study of human transmissible spongiform
encephalopathies has been carried out from 1993 to 2000
and includes data from 10 national registries, the majority
in Western Europe. In this study, we present analyses of
predictors of survival in sporadic (n = 2304), iatrogenic
(n = 106) and variant Creutzfeldt–Jakob disease (n = 86)
and in cases associated with mutations of the prion protein
gene (n=278), includingGerstmann–Stra¨ussler–Scheinker
syndrome (n = 24) and fatal familial insomnia (n = 41).
Overall survival for each disease type was assessed by the
Kaplan–Meier method and the multivariate analyses by
the Cox proportional hazards model. In sporadic disease,
longer survival was correlated with younger age at onset of
illness, female gender, codon 129 heterozygosity, presence
of CSF 14-3-3 protein and type 2a prion protein type. The
ability to predict survival based on patient covariates is
important for diagnosis and counselling, and the charac-
terization of the survival distributions, in the absence of
therapy, will be an important starting point for the assess-
ment of potential therapeutic agents in the future.
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Introduction
Human transmissible spongiform encephalopathies (TSEs)
or prion diseases comprise a number of conditions with vary-
ing aetiology and include sporadic Creutzfeldt–Jakob
disease (sCJD), iatrogenic CJD (iCJD), variant CJD (vCJD)
and cases associated with mutations of the prion protein gene
(PRNP) (gTSE). Within the latter group are genetic forms
of CJD (gCJD), for example cases linked to mutations at
codon 200 and codon 210 of PRNP, Gerstmann–
Stra¨ussler–Scheinker syndrome (GSS) and fatal familial
insomnia (FFI) (Pocchiari, 1994). The clinical phenotypes
of the subtypes of human TSE vary, and this variation is
determined in part by the polymorphism at codon 129 of
PRNP (Collinge et al., 1991; Palmer et al., 1991; Kovacs
et al., 2002) and the type of prion protein deposited in the
brain (Parchi et al., 1996). One important variable is the total
duration of clinical illness, also termed survival, and this
parameter can be useful in clinical diagnosis of the various
forms of human TSE, including sCJD (Brown et al., 1994). In
genetic cases, iCJD cases following human growth hormone
therapy (ihGH) and vCJD, survival is more prolonged than in
sCJD, but considerable variation in survival is seen within all
subtypes of human TSE.
Variables that are thought to influence survival are age
(with a reduction in survival with increasing age in sCJD;
Puopolo et al, 2003), the codon 129 genotype and the type of
prion protein deposited in the brain. There have been sugges-
tions of a gender effect on the incidence of sCJD (Will et al.,
1986; Brown et al., 1987), but this has been inconsistent
between studies (Galvez et al., 1980; Lundberg, 1998). The
identification of significant and consistent predictors/
determinants of survival is a difficult task because of the rarity
of human TSEs, but establishing definitive factors that influ-
ence disease phenotype, including survival, may lead to clues
to the underlying pathogenic mechanisms and to improved
case recognition and clinical discrimination between the var-
ious disease subtypes.
The renewed interest in developing specific therapies for
human TSEs (Brown, 2002; Korth et al., 2002) has high-
lighted the importance of clearly delineating the natural his-
tory of these disorders. Establishing the expected survival and
the variables that influence survival in a cohort of untreated
cases is likely to provide a crucial baseline to assessing the
effectiveness of novel therapies. If, for example, age and gen-
der are important determinants of survival, it may be crucial to
include these variables in the assessment of whether or not an
intervention actually prolongs survival. It is known that sur-
vival is variable in sCJD, with some cases presenting acutely
(McNaughton and Will, 1994) and others surviving for many
years (Brown et al., 1984). The aim of this paper is to define
predictors of survival in all forms of human TSE and to
quantify these effects as accurately as possible.
Patients and methods
Patients with all forms of human TSEs were ascertained by
national surveillance centres as part of a prospective CJD
surveillance programme funded by the European Union.
Those patients fulfilling the validated diagnostic criteria for
definite or probable TSEs were included in a common data-
base. The database contained core medico-demographic
information on all TSE cases who died between 1993 and
2000 for Australia, France, Germany, Italy, The Netherlands,
Slovakia and the UK, and between 1998 and 2000 for Austria,
Spain and Switzerland. Detailed descriptions of the study
methodology have been published (Will et al., 1998a).
TSE patients were classified as sCJD, iCJD, vCJD and gTSE
according to previously published diagnostic criteria. This last
group includes gCJD, GSS, FFI and cases carrying an insert
mutationof thePRNPgene (althoughpatients withgTSEscarry
a mutation of the PRNP gene, it is not yet clear whether the
mutation is the cause of disease or a predisposing factor). Iatro-
genic cases were also divided into two categories according to
whether they developed the disease following therapy with
native human cadaveric growth hormone (ihGH) or after
human dura mater implant (iDM). The protease-resistant
prion protein type (PrPSc) found in the brain was classified
according to the two-type system published by Parchi et al.
(1999). Survival was defined as the interval between disease
onset and death. Dates of death were available from direct
notification by clinicians, from hospital records or from
death certificates. The date of onset of clinical symptoms
was defined in each case after review of hospital records, clin-
ical correspondence and/or interview with the patient’s family.
In the great majority of cases, there was little difficulty in defin-
ing the date of onset, but in some cases a judgement was made
based on information from a range of sources. In Germany,
attribution of the date of onset was dependent solely on infor-
mation from relatives.
Statistical analysis
We investigated the effect on survival of the following demo-
graphic, clinical and laboratory investigation variables: sex,
age at onset, polymorphism at codon 129 of the PRNP gene,
country participating in the study, EEG pattern, presence of
protein 14-3-3 in the CSF and PrPSc type.
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Survival curves were estimated by the Kaplan–Meier
method, both overall and by stratifying for each of the
above variables.
For each form of TSE, we report as descriptive statistics the
median survival times overall and stratified for each variable;
the comparisons of survival curves between groups were car-
ried out by the generalized Wilcoxon test. The Cox propor-
tional hazards model was used to assess the independent
effects of the investigated factors by a multivariate analysis.
Crude relative risk (RR) and adjusted RR with 95% confi-
dence intervals (CIs) were generated. We used the ‘cluster’
function on the STATA program for the categorical variable
‘country’. The ‘cluster’ function is used to specify non-
independent observations, such as all patients observed in
each country, in order to allow robust calculations of stand-
ard errors.
Age (in years) at onset was analysed as a continuous
variable for 10 year increments. The relative risk for codon
129 was estimated by including two dummy variables with
methionine/methionine (MM) as reference.
For sCJD, the multivariate model was used first by includ-
ing only the gender, the age at onset and the codon 129
polymorphism, because this set contained the largest number
of data (n = 1452). The Cox model was then used on smaller
samples with available data for EEG characteristics and pre-
sence of the 14-3-3 protein in the CSF (n = 893) or PrPSc type
(n = 420). The distributions of sex, age at onset and codon 129
status in these different data sets were compared by the x2 test
to confirm that missing values were not selected for any of the
considered variable. The x2 test was also adopted to assess
dependency between categorical variables.
The Bonferroni correction for multiple testing was adopted
within the five subgroups of gTSE (E200K and V210I gCJD,
GSS, FFI and insert mutations) and the two subgroups of iCJD
patients. This correction was not applied for all forms of
human TSEs since sCJD, iCJD, vCJD and gTSEs are distinct
diseases with different aetiology. Thus, the critical level of
significance for gTSE was 0.01 (five subgroups) and for iCJD
0.025 (two subgroups).
Statistical analyses were performed using BMDP and
STATA.
Results
The mean and median survival times for the different forms
of TSEs are summarized in Table 1. SCJD, gCJD and iDM
had the shortest median survival times of <6 months; ihGH,
vCJD, FFI and gTSE with insert mutations had median
clinical durations of 1 year, while that for GSS patients
exceeded 3 years.
Kaplan–Meier survival curves for sCJD, iCJD and vCJD
are shown in Fig. 1A, and for gTSE in Fig. 1B. One year after
clinical onset, only a few patients with sCJD (15%), iDM
(15%) or gCJD (8%) were still alive, while about half the
patients with ihGH (54%), vCJD (55%), FFI (48%) and gTSE
with insert mutations (55%) survived. About 80% of GSS
patients were still alive 1 year after clinical onset.
Sporadic CJD
sCJD patients from Germany had a significantly (P < 0.0001)
longer median duration (6 months, n = 568) of illness than
patients from all the other countries: 5 months for Spain (n =
123), 4.5 months for Switzerland (n = 43), and 4 months for
Australia (n = 149), Austria (n = 29), France (n = 543), Italy
(n = 379), Slovakia (n = 12), The Netherlands (n = 70) and the
UK (n = 388).
Univariate survival analyses of sCJD cases with available data
(see Table 2) showed differences in the duration of illness by
gender (Fig. 2A), age at onset (Fig. 2B) and the polymorphism
at codon 129 of the PRNP gene (Fig. 2C). The multivariate
analysis confirmed that survival is longer in females compared
with males and showed that increments of 10 years in the age at
onset are associated with an 30% increase in risk of death
(Table 3A). Survival was shorter in patients who were MM at
codon 129 of the PRNP gene (Table 3A) compared with that
seen in valine/valine (VV) and methionine/valine (MV) cases.
When we include a dummy variable in the Cox multivariate
model indicating whether patients were from Germany or
other countries, the RR for all the above parameters did
not change, but the clinical duration of German sCJD patients
still remained significantly longer (adjujsted RR = 0.78; CI
0.74–0.83, P < 0.001) than that in other countries.
Two investigational features were considered as possible
predictive markers of survival: periodic sharp wave com-
plexes (PSWC) in the EEG, the ‘typical’ pattern in sCJD,
and the presence of the 14-3-3 protein in the CSF. In the
univariate analysis, survival was significantly shorter in
patients with PSWC than in patients without PSWC and in
patients with a positive versus negative 14-3-3 test (Table 2).
When the EEG pattern and the 14-3-3 test were included in
Table 1 Clinical duration of disease in different forms
of TSEs
Mean survival
time months
(SEM)
Median survival
time months
Sporadic CJD (n = 2304) 7.3 (0.2) 5
Genetic TSE
Genetic CJD (n = 191) 6.3 (0.5) 4
FFI (n = 41) 15.6 (2.2) 12
GSS (n = 24) 42.7 (6.1) 39
Insert (n = 22) 46.9 (12.8) 14
Iatrogenic CJD*
hGH CJD (n = 85) 14.7 (0.9) 13
DM CJD (n = 20) 9.4 (2.4) 5.5
Variant CJD (n = 86) 15.3 (0.8) 13
FFI = fatal familial insomnia; GSS = Gerstmann
Straussler–Scheinker syndrome; hGH = human growth hormone;
DM = dura mater. *A single case of iatrogenic CJD following
corneal transplant had a survival of 11 months.
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the Cox regression model with sex, age at onset and codon 129
polymorphism, the 14-3-3 test, but not the EEG, retained
significance in determining clinical duration of disease
together with the other three parameters (Table 3A and B).
The reason for the lack of significance in the multivariate
analysis for the EEG variable is likely to be because a typical
EEG is more frequently observed in patients with late clinical
onset (78% of patients >80, 73% in age class 71–80, 69% in
61–70, 58% in 51–60 and 47% of patients <50 years, P <
0.0001, x2 test), and in patients homozygous for methionine at
codon 129 (80% of MM, 51% of MV and 31% of VV patients,
P < 0.0001, x2 test), representing groups of patients with the
shortest survival. The missing data for EEG and 14-3-3 were
randomly distributed (x2 tests for the comparison of the dis-
tributions in the two data sets: P = 0.97 for gender,P = 0.54 for
age at onset and P = 0.66 for codon 129).
PrPSc type analysis was available for 450 subjects. Uni-
variate analyses (Fig. 2D) showed that patients with the PrPSc
type 1 had a significantly shorter survival than PrPSc type 2a
(Table 2). When PrPSc type was included with sex, age at
onset and PRNP polymorphism at codon 129 in the Cox
regression model, the genotype lost its effect on survival
(Table 3A and C). This was mostly due to the concomitant
fact that there was an uneven distribution of codon 129 poly-
morphism between PrPSc type 1 (MM = 87.9%, VV = 3.7%,
MV = 8.4%) and type 2a (MM = 21.1%, VV = 47.2%, MV =
31.7%) (P < 0.0001, x2 test), and an increased proportion of
MV and VV patients (with longer clinical duration) in PrPSc
type 2a with respect to type 1. The missing data for PrPSc type
were randomly distributed (x2 tests for the comparison of the
distributions in the two data sets: P = 0.23 for gender, P = 0.80
for age at onset and P = 0.97 for codon 129).
The crude RR for gender, age at onset and codon 129
obtained in the univariate Cox regression models (Table 3)
did not vary when estimated in different subgroups of patients
where data on EEG and 14-3-3 test (n = 893) or on PrPSc type
(n = 420) were available.
Fig. 1 Kaplan–Meier survival curves in (A) sporadic CJD, variant CJD, dura-mater related CJD and human growth hormone-related CJD;
(B) genetic TSEs, including genetic CJD, GSS, FFI and insert mutations.
Table 2 Survival time for sporadic CJD
Features Median
(months)
P (generalized
Wilcoxon test)
Overall (n = 2304) 5
Gender
Male (n = 998) 4 <0.0001
Female (n = 1304) 5
Age at onset
11–20 (n = 2) 54, 58* <0.0001
21–30 (n = 6) 21
31–40 (n = 14) 23
41–50 (n = 95) 7
51–60 (n = 425) 6
61–70 (n = 937) 5
71–80 (n = 703) 4
81–90 (n = 120) 3
91–100 (n = 2) 2, 3*
Codon 129
MM (n = 993) 4 <0.0001
MV (n = 227) 9
VV (n = 233) 6
EEG
PSWC (n = 1429) 4 <0.0001
No PSWC (n = 683) 6
14-3-3 in CSF
Positive (n = 1254) 5 <0.0001
Negative (n = 104) 9
PrP type
Type 1 (n = 319) 4 <0.0001
Type 2a (n = 131) 8
*Observed values.
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Genetic TSEs
Survival in gCJD patients differed between the various muta-
tions of the PRNP gene (Table 4). An analysis was only
performed for the two most frequent PRNP mutations (i.e.
E200K and V210I). Median clinical duration (Table 5) for
E200Kand V210I patients was 4 months. In the univariate
Cox analysis, survival of both E200K and V210I patients was
shorter in males than in females. Though both mutations co-
segregate with methionine at codon 129, methionine homo-
zygosity was associated with a shorter survival in E200K
patients, but a long survival in V210I patients (Table 5,
Fig. 3). Survival was significantly shorter in patients with
late age at onset only in V210I patients (Table 5). Multivariate
analyses confirmed the significance of all variables for V210I
patients (Table 5). In E200K patients, the only significant
predictor of survival remained the polymorphism at codon
129. The effect of gender just missed statistical significance
when correcting for multiple testing (Table 5).
In FFI (D178N) patients, only the polymorphism at codon
129 of the PRNP gene significantly affected survival
(Table 6). MV patients showed a longer survival than MM
patients.
In gTSE with insert mutations, survival was influenced by
the age at onset and codon 129 polymorphism (Table 6). The
multivariate analysis with age at onset and codon 129 showed
that only MV patients had a significantly longer survival than
MM patients (adjusted RR for age at onset = 1.88, CI
0.82–4.30, P = 0.133; adjusted RR for MM versus MV,
0.31, CI 0.20–0.48, P < 0.001; adjusted RR for MM versus
VV = 0.81, CI 0.38–1.71, P = 0.583). We did not analyse the
relationship between survival and the size of the insert
because of the small numbers of cases.
3/4
Fig. 2 Kaplan–Meier survival curves in sporadic CJD by (A) gender, (B) age at onset, (C) codon 129 genotype and (D) prion protein
isotype.
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In GSS, methionine homozygous patients at codon 129
showed a median survival time 36 months longer than hetero-
zygous patients. However, due to the small sample size and
to the correction for multiple testing in the gTSE group, the
difference did not reach statistical significance (Table 6).
Iatrogenic CJD
In ihGH CJD cases, a significantly lower risk was found for
females compared with males and a higher risk for patients
with late versus early age at onset. Survival curves were
different in patients carrying distinct polymorphisms at
codon 129 (Table 7, Fig. 3). However, this parameter was
not significant in the univariate Cox analysis when MM
patients were considered as the reference group. The multi-
variate Cox model with gender and age at onset confirmed
these results (adjusted RR for gender = 0.75, CI 0.63–0.89,P =
0.001; adjusted RR for age at onset = 1.56, CI 1.35–1.81, P <
0.001). It is likely that the loss of significance for codon 129
was because the median survival of MM cases was between
those of MV and VV cases. When we used VV cases as the
reference group (those with the shortest median survival), the
MV cases showed a lower risk than VV cases (crude RR =
0.41; 95% CI = 0.26–0.65, P < 0.001).
In iDM CJD cases, no significant effect of gender or age at
onset was found by the Cox univariate model (Table 7). We
did not analyse the effect of the codon 129 polymorphism
because there were only two MV and one VV patients.
Variant CJD
Since all vCJD patients were MM, only the effect of
gender and age at onset as predictors of survival was
analysed. A significantly longer median illness duration
was observed in females compared with males and in patients
with early compared with late age at onset. These findings
were confirmed by the Cox univariate and multivariate
analyses (Table 8).
Table 3 Cox regression model for survival in sporadic CJD patients
Features Crude RR (95% CI) Adjusted RR (95% CI)
for A (n = 1452) for A and B (n = 893) for A and C (n = 420)
A
Gender
Male 1 1 1 1
Female 0.85 (0.73–0.99)*
(P = 0.045)
0.74 (0.63–0.88)
(P = 0.001)
0.74 (0.67–0.82)
(P < 0.001)
0.76 (0.62–0.94)
(P = 0.010)
Age at onsetþ 1.34 (1.28–1.40)*
(P < 0.001)
1.34 (1.28–1.40)
(P < 0.001)
1.30 (1.20–1.40)
(P < 0.001)
1.39 (1.34–1.44)
(P < 0.001)
Codon 129
MM 1 1 1 1
MV 0.55 (0.44–0.70)*
(P < 0.001)
0.55 (0.45–0.67)
(P < 0.001)
0.61 (0.46–0.80)
(P < 0.001)
0.80 (0.49–1.31)
(P = 0.379)
VV 0.70 (0.61–0.80)*
(P < 0.001)
0.77 (0.67–0.88)
(P < 0.001)
0.82 (0.71–0.94)
(P = 0.005)
1.34 (0.86–2.08)
(P = 0.197)
B
EEG
PSWC 1 – 1 –
No PSWC 0.79 (0.65–0.96)
(P = 0.020)
– 1.01 (0.86–1.19)
(P = 0.905)
–
14-3-3 in the CSF –
Positive 1 – 1
Negative 0.62 (0.43–0.88)
(P = 0.007)
– 0.71 (0.52–0.96)
(P = 0.027)
–
C
PrPSc glycotype
Type 1 1 – – 1
Type 2a 0.54 (0.43–0.68)
(P < 0.001)
– – 0.53 (0.43–0.64)
(P < 0.001)
*Crude RR did not change when estimated for A and B and A and C; þcontinuous for increment of 10 years.
Table 4 Clinical duration of disease in genetic CJD patients
carrying different point mutations of the PRNP gene
PRNP mutations Median (months)
D178N-129V (n = 8) 9
T188R (n = 1) 2*
E196K (n = 1) 13*
E200K (n = 123) 4
V203I (n = 2) 2, 4*
R208H (n = 1) 10*
V210I (n = 48) 4
E211Q (n = 5) 4
Observed values.
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Discussion
The findings presented in this paper are generally consistent
with previous studies of survival in sCJD (Wientjens, 1997;
Will et al., 1998a; Parchi et al., 1999; Puopolo et al., 2003),
but the large number of cases included in our analysis allows a
more detailed description of predictors that influence survival
in all forms of human TSE. There are a number of noteworthy
and novel findings, including the influence of gender on sur-
vival in a number of subtypes of human TSE and the effect of
prion protein PrPSc type on survival in sCJD. A reduction in
survival with increasing age has been confirmed in sCJD,
gCJD, cases with insert mutations and vCJD.
In order to allow comparability of data, it is essential to
achieve consistency of data collection between countries.
Details of the methodology of the study have been described
previously (Will et al., 1998a). In this paper, there is a
remarkable consistency in the results from country to coun-
try, for example in the median duration of illness in sCJD.
The exception is a significant increase in the median survi-
val in sCJD in Germany in comparison with the other coun-
tries (4 months in the majority compared with 6 months in
Germany). The reason for this finding may be because of a
systematic difference in classification of the time of disease
onset. However, the analyses are not affected by this anom-
aly. The numbers of cases in this study are larger than any
previous series, allowing firm conclusions on the major
predictors of survival in sCJD. However, the numbers of
cases in the subtype analyses are smaller, and this may
result in insufficient power to assess some parameters
properly.
Assessment of survival by disease type (Fig. 1A and B)
demonstrates differences in illness duration between the var-
ious forms of human TSE. The shortest survival is in sCJD,
iDM and, perhaps surprisingly, in some forms of gCJD. It is
important to stress that the surveillance system depends on
referral of suspect cases from neurologists, and this may result
in a bias in the identification of genetic cases with a phenotype
similar to sporadic cases (Will et al., 1998b). In vCJD, ihGH
and FFI, a small proportion of patients survive to 24 months,
which contrasts with GSS and cases associated with insert
mutations in which a significant proportion survive beyond
24 months. In sCJD, about one in seven cases survives to
1 year and one in 30 to 2 years.
A reduction in survival with increasing age in sCJD is well
known (Wientjens, 1997) but is not well documented. In
this study, survival was found to decrease significantly with
Table 5 Survival times for genetic CJD (E200K and V210I)
Features E200K V210I
Median in months P* Median in months P*
Overall 4 (n = 123) 4 (n = 48)
Gender
Male 3 (n = 48) 0.020 3 (n = 22) 0.060
Female 5 (n = 75) 5 (n = 26)
Age at onset
31–40 14, 20þ (n = 2) 0.067 5þ (n = 1) 0.0047
41–50 6 (n = 20) 4 (n = 10)
51–60 5 (n = 36) 5 (n = 14)
61–70 3 (n = 41) 3 (n = 15)
71–80 3 (n = 20) 2 (n = 7)
81–90 3 (n = 4) 4y (n = 1)
Codon 129
MM 4 (n = 88) 0.002 5 (n = 38) 0.04
MV 8 (n = 23) 3 (n = 9)
VV 4, 7þ (n = 2) – (n = 0)
Cox regression model for survival in genetic E200K and V210I CJD patients
Features E200K (n = 111) V210I (n = 47)
Crude RR (95% CI) Adjusted RR (95% CI) Crude RR (95% CI) Adjusted RR (95% CI)
Gender
Male 1 1 1 1
Female 0.75 (0.60–0.92)
(P = 0.007)
0.78 (0.63–0.95)
(P = 0.015)
0.76 (0.64–0.90)
(P = 0.002)
0.79 (0.67–0.93)
(P = 0.004)
Age at onset
y
1.13 (1.01–1.27)
(P = 0.048)
1.13 (0.98–1.29)
(P = 0.090)
1.39 (1.24–1.56)
(P < 0.001)
1.51 (1.42–1.62)
(P < 0.001)
Codon 129
MM 1 1 1 1
MV 0.57 (0.50–0.65)
(P < 0.001)
0.56 (0.45–0.70)
(P < 0.001)
2.17 (1.51–3.11)
(P < 0.001)
2.67 (2.10–3.39)
(P < 0.001)
*Generalized Wilcoxon test; þobserved values; ycontinuous for increment of 10 years.
2354 M. Pocchiari et al.
increasing age in sCJD (Fig. 2B) with, for example, 10% of
cases aged >80 years surviving at 6 months in comparison with
60% of cases aged <50 years. A similar age effect on survival
is seen incasesassociated with mutationsofPRNPat codon 210
and in insert mutations. In ihGH, there is also a borderline
relationship between prolonged survival and younger age,
and there is a trend in a similar direction with vCJD. The
most obvious difference between the ihGH cases and vCJD
in comparison with the other subtypes is the relatively young
age at death (Brown, 1988; Will et al., 2000). It is possible that
shouldcasesof iatrogenicorvCJDoccur in theolderagegroups,
the relationship between survival and age would become more
significant as in the other forms of human TSE. The single case
ofvCJDin theolderagegroupdiedat theageof74yearsandhad
one of the shortest illness durations yet seen of 7 months (Henry
etal.,2002).Thereasonfor the inverserelationshipbetweenage
and survival in the majority of subtypes of human prion disease
is unknown and, although age-related variations in care or
resistance to terminal infection may play a role, there is evi-
dence from laboratory studies of age-related effects on patho-
genesis (Bruce and Fraser, 1982; Manolakou et al., 2001).
The overall female : male ratio in sCJD in this study, based
on sex-specific mortality rates, is 1.24, representing a signific-
ant excess of female cases. A female preponderance in sCJD
has been documented previously, but this finding is not con-
sistent between studies, even in those carried out systematic-
ally (Brown, 1998). Because sCJD is predominantly a disease
in the older age groups (60–79 years) and life expectancy is
longer in females, population demographics may influence the
overall sex distribution. However, this ratio may be affected
by the uneven distribution of cases in different age classes,
and a better estimate is given by the average female to male
Fig. 3 Influence of codon 129 genotype on Kaplan–Meier survival curves in (A) E200K CJD, (B) V210I CJD, (C) FFI, (D) human growth
hormone-related CJD.
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Table 6 Survival times for FFI, GSS and patients with insert mutations
Features FFI GSS Insert
Median in
months
P* Crude RR
(95% CI)
Median in
months
P* Crude RR
(95% CI)
Median in
months
P* Crude RR
(95% CI)
Overall 12.0 (n = 41) 39.0 (n = 24) 14.0 (n = 22)
Gender
Male 12.0 (n = 24) 0.43 1 30.5 (n = 9) 0.59 1 32.5 (n = 11) 0.53 1
Female 12.5 (n = 17) 0.92
(0.69–1.24)
(P = 0.590)
39.5 (n = 15) 0.66
(0.20–2.17)
(P = 0.490)
8.5 (n = 11) 1.61
(0.62–4.20)
(P = 0.326)
Age at
onsetþ
21–30 – 0.65 0.82
(0.60–1.13)
(P = 0.227)
7, 70y (n = 2) 0.52 1.19
(0.85–1.66)
(P = 0.305)
– 0.018 2.00
(1.62–2.47)
(P < 0.001)
31–40 11.0 (n = 6) 8, 32y (n = 2) 93.0 (n = 4)
41–50 13.5 (n = 9) 46.0 (n = 9) 86.0 (n = 4)
51–60 12.5 (n = 19) 20.0 (n = 5) 5.0 (n = 4)
61–70 12.0 (n = 6) 29.5 (n = 3) 8.0 (n = 7)
71–80 – 3, 67y (n = 2) 4, 5y (n = 2)
81–90 – – 4y (n = 1)
Codon 129
Met/Met 11.0 (n = 26) 0.0026 1 44.0 (n = 6) 0.19 1 4.0 (n = 7) 0.13 1
Met/Val 20.0 (n = 12) 0.15
(0.06–0.39)
(P < 0.001)
8.0 (n = 6) 2.56
(1.03–6.39)
(P = 0.044)
40.0 (n = 5) 0.28
(0.12–0.66)
(P = 0.003)
Val/Val – – 5.0 (n = 5) 0.52
(0.16–1.71)
(P = 0.280)
*Generalized Wilcoxon test; þcontinuous for increment of 10 years; yobserved values.
Table 7 Survival times for iatrogenic-hGH and iatrogenic-DM CJD
Features Iatrogenic-hGH CJD Iatrogenic-DM CJD
Median in months P* Crude RR (95% CI) Median in months P* Crude RR (95% CI)
Overall 13.0 (n = 85) 5.5 (n = 20)
Gender 0.19 0.38
Male 13.0 (n = 62) 1 5.0 (n = 12) 1
Female 14.0 (n = 23) 0.61 (0.60–0.63)
(P < 0.001)
6.0 (n = 8) 0.78 (0.34–1.76)
(P = 0.546)
Age at onsetþ 0.014 1.69 (1.41–2.02)
(P < 0.001)
0.0008 1.17 (0.90–1.53)
(P = 0.242)
10 36y (n = 1) –
11–20 25.0 (n = 8) –
21–30 11.5 (n = 59) 7.0 (n = 5)
31–40 12.5 (n = 17) 4.0 (n = 3)
41–50 – 5.0 (n = 4)
51–60 – 4.5 (n = 5)
61–70 – 2y (n = 1)
71–80 – 3, 11y (n = 2)
Codon 129 0.0065 0.70
Met/Met 13.0 (n = 38) 1 6.0 (n = 9) –
Met/Val 17.0 (n = 19) 0.59 (0.30–1.19)
(P = 0.141)
5, 8y (n = 2) –
Val/Val 9.0 (n = 19) 1.46 (0.46–4.63)
(P = 0.522)
5y (n = 1) –
*Generalized Wilcoxon test; þcontinuous for increment of 10 years; yobserved values.
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ratios of each 10 year age class interval, weighting for the
number of cases in each age class. The weighted female to
male ratio is 1.08, but this still represents an 8% excess of
female cases. The excess of female cases in sCJD does not
explain the significant difference in survival in sCJD, with
females surviving a median of 1 month longer than males.
Similar gender effects on survival were found in cases asso-
ciated with mutations of PRNP, with the exception of FFI,
and in vCJD.
The effect of gender has been studied in mouse models,
with varying results. One study has shown a major influence
of gender in experimental transmission of bovine spongiform
encephalopathy (BSE), with extended incubation periods in
females (Abiola et al., 2002). In contrast, a recent study of
non-PRNP genetic influences on incubation period showed a
significant reduction in the incubation period in females
(Manolakou et al., 2001), consistent with previous studies
(Bruce and Dickinson, 1985; McLean and Bostock, 2000).
The excess of female cases and the prolonged female survival
in a number of types of human TSE suggest that there are
sex-specific factors that influence the clinical phase of
human disease. Possibilities include genetic determinants
outside the PRNP gene, hormonal effects or neuro-
anatomical factors.
Prolonged survival is one of the variables that distinguish
the subtypes of CJD classified according to the seminal work
by Parchi and colleagues, using PrPSc type and codon 129
genotype (Parchi et al., 1991). The findings in our study
support the hypothesis that the type of protein deposited in
the brain influences the clinical phenotype. There is a clear
and significant effect on survival in sCJD according to PrPSc
type, with more prolonged survival in cases with the type 2a
prion protein. One caveat to this conclusion is that there is
evidence in some cases of sCJD of deposition of more than
one PrPSc type in the brain (Puoti et al., 1999) and in our study
there was no consistency in the brain area from which protein
was extracted. Whether the PrPsc type correlates with different
‘strains’ of infectious agent remains unproven.
There has been a recent resurgence of interest in identifying
potential therapies for human TSEs, including CJD (Brown,
2002; Knight, 2002). Drug trials are likely to pose many
difficulties, not least because of the rarity of CJD, and com-
parison of outcome, including survival, in treated cases in
relation to the natural history may be an important strategy
in assessing the efficacy of potential treatments. The detailed
analyses in this study are likely to constitute important con-
siderations for the assessment of treatment efficacy in human
TSEs because of the identification and quantification of vari-
ables that influence survival in various TSE subtypes. This
study documents the influence of a range of variables on
survival in a population of cases that were not treated with
any therapy known to influence the underlying disease pro-
cess. A number of variables have been identified that have an
influence, and often a major influence, on survival, including
age, gender and codon 129 genotype. Although variables such
as the PrPSc type may be of clinical use in the future by using
nervous tissue taken from the biopsy of the olfactory epithe-
lium (Zanusso et al, 2003), the results of investigations
including the 14-3-3 CSF immunoassay correlate with survi-
val. A ‘typical’ EEG is associated with shortened survival
(Zerr et al., 2000) and a negative 14-3-3 test with relatively
prolonged survival. In this study, the multivariate regression
analysis has shown that only the 14-3-3 result is an independ-
ent predictor of survival, with a positive result probably
reflecting rapid neuronal damage. In the univariate analysis,
patients with a typical EEG had a significantly shorter survival
than patients with non-specific EEG findings. This signific-
ance was lost in the multivariate analysis because the EEG
pattern strongly correlates with the polymorphism at codon
129 of the PRNP gene. A possible explanation is that a typical
EEG is likely to be related to the site of lesions in the brain,
which in turn depends on the polymorphism at codon 129
(Tschampa et al., 2002).
This study underlines the importance of collaborative
research in a rare disease. Some of the findings are novel,
but attaining statistical significance has depended on the pool-
ing of results from 10 countries carrying out national surveil-
lance for human TSEs. The detailed analyses of factors
influencing survival raise a number of scientific questions,
for example the mechanism by which gender influences
Table 8 Survival times for vCJD patients
Features Median in months P* Crude RR (95% CI) Adjusted RR (95% CI)
Overall 13.0 (n = 86)
Gender 0.035
Male 12.0 (n = 45) 1 1
Female 14.0 (n = 41) 0.69 (0.61–0.79) (P < 0.001) 0.76 (0.68–0.85) (P < 0.001)
Age at onsetþ 0.005 1.26 (1.25–1.28) (P < 0.001) 1.22 (1.18–1.26) (P < 0.001)
11–20 14.0 (n = 18)
21–30 13.0 (n = 39)
31–40 12.0 (n = 20)
41–50 7.0 (n = 4)
51–60 11.0 (n = 4)
61–70 –
71–80 7y (n = 1)
*Generalized Wilcoxon test; þcontinuous for increment of 10 years; yobserved values.
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disease expression, and may be critical in assessing the effi-
cacy of novel therapeutic strategies.
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